About the event

Held over a weekend, the event is structured around a series of exhibitions, workshops, and panel discussions. The exhibitions showcase a curated selection of photographs that tell compelling stories from various corners of the globe, each image accompanied by detailed narratives that provide context and deeper insight into the historical significance of the scenes depicted. These photographs are drawn from the archives of renowned photographers, as well as emerging talents, ensuring a blend of both classical and contemporary perspectives.

Cliff Palace, Colorado
In the Green: BridgeBio Oncology Therapeutics Inc (BBOT) Closes at $12.18, Up/Down -1.46% from Previous Day – DwinneX

In the Green: BridgeBio Oncology Therapeutics Inc (BBOT) Closes at $12.18, Up/Down -1.46% from Previous Day

Ulysses Smith

In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.

In the latest session, BridgeBio Oncology Therapeutics Inc (NASDAQ: BBOT) closed at $12.18 down -1.46% from its previous closing price of $12.36. In other words, the price has decreased by -$1.46 from its previous closing price. On the day, 98868.0 shares were traded. BBOT stock price reached its highest trading level at $12.68 during the session, while it also had its lowest trading level at $12.095.

Ratios:

For a deeper understanding of BridgeBio Oncology Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 13.33 and its Current Ratio is at 13.33. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.

Upgrades & Downgrades

In the most recent recommendation for this company, Leerink Partners on September 17, 2025, initiated with a Outperform rating and assigned the stock a target price of $25.

On September 15, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $27.

On August 15, 2025, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $21.Piper Sandler initiated its Overweight rating on August 15, 2025, with a $21 target price.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBOT now has a Market Capitalization of 974262272 and an Enterprise Value of 508864192.

Stock Price History:

The Beta on a monthly basis for BBOT is 0.11, which has changed by 0.18277514 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, BBOT has reached a high of $14.04, while it has fallen to a 52-week low of $8.50. The 50-Day Moving Average of the stock is 2.00%, while the 200-Day Moving Average is calculated to be 11.53%.

Shares Statistics:

For the past three months, BBOT has traded an average of 240.48K shares per day and 132160 over the past ten days. A total of 79.20M shares are outstanding, with a floating share count of 43.18M. Insiders hold about 46.02% of the company’s shares, while institutions hold 52.78% stake in the company. Shares short for BBOT as of 1763078400 were 976866 with a Short Ratio of 4.06, compared to 1760486400 on 763171.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.